British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011

British Journal of Dermatology

Volumn 165, Issue 4, 2011, Pages 711-734

  Meggitt, S J ^a   Anstey, A V ^b   Mohd Mustapa, M F ^c   Reynolds, N J ^d   Wakelin, S ^e  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

^c BRITISH ASSOCIATION OF DERMATOLOGISTS   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMINOSALICYLIC ACID; ANTIEMETIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CLOZAPINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FAMCICLOVIR; FEBUXOSTAT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LIVE VACCINE; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RIBAVIRIN; THIOPURINE METHYLTRANSFERASE; TRIMETHOPRIM; TUMOR NECROSIS FACTOR INHIBITOR; VALACICLOVIR; VARICELLA ZOSTER VACCINE; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ATOPIC DERMATITIS; BEHCET DISEASE; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BULLOUS PEMPHIGOID; CANCER RISK; CARCINOGENESIS; CHICKENPOX; CHILD CARE; CHILDHOOD LEUKEMIA; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DERMATITIS; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELDERLY CARE; ENTERITIS; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE ACTIVITY; GENE MUTATION; GENOTYPE; HEALTH CARE COST; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION SENSITIVITY; KIDNEY DISEASE; KIDNEY FUNCTION; LACTATION; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOPENIA; LICENSING; LIVER DISEASE; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; LYMPHOCYTOPENIA; LYMPHOMA; MAINTENANCE DRUG DOSE; MALE FERTILITY; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; ORGAN TRANSPLANTATION; PANCREATITIS; PANCYTOPENIA; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PEMPHIGOID; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PHARMACOGENETICS; PHENOTYPE; PITYRIASIS RUBRA PILARIS; POLYMYOSITIS; PRACTICE GUIDELINE; PRECANCER; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN DISEASE; SKIN TOXICITY; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT; VASCULITIS; VIRUS HEPATITIS; VOMITING; WEGENER GRANULOMATOSIS;

ABNORMALITIES, DRUG-INDUCED; ADULT; AGED; AZATHIOPRINE; BONE MARROW DISEASES; CHILD; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; DRUG COSTS; DRUG HYPERSENSITIVITY; DRUG INTERACTIONS; DRUG-INDUCED LIVER INJURY; FEMALE; GENETIC TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY DISEASES; LACTATION; MALE; METHYLTRANSFERASES; NAUSEA; NEOPLASMS; OFF-LABEL USE; PATIENT EDUCATION AS TOPIC; PREGNANCY; RISK FACTORS; SKIN DISEASES; THIOGUANINE; VIRUS DISEASES;

EID: 80053484439     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10575.x     Document Type: Review

References (183)

1. Bell HK, Ormerod AD,. Writing a British Association of Dermatologists clinical guideline: an update on the process and guidance for authors. Br J Dermatol 2009; 160: 725-8.
2. The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. 2001. Available at: (last accessed 2 August 2011).
3. Weinshilboum RM, Sladek SL,. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62. (Pubitemid 10061685)
4. Newman WG, Payne K, Tricker K, et al. A pragmatic randomised controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics 2011; 12: 815-26.
5. Slanar O, Chalupna P, Novotny A, et al. Fatal myelotoxicity after azathioprine treatment. Nucleosides Nucleotides Nucleic Acids 2008; 27: 661-5. (Pubitemid 351948569)
6. Boonsrirat U, Angsuthum S, Vannaprasaht S, et al. Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism. Lupus 2008; 17: 132-4. (Pubitemid 351346447)
7. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-18. (Pubitemid 28507145)
8. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-8.
9. Lennard L, Van Loon JA, Weinshilboum RM,. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-54. (Pubitemid 19219950)
10. Lennard L, Lilleyman JS, Van Loon J, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-9. (Pubitemid 20229068)
11. Wang L, Weinshilboum R,. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006; 25: 1629-38.
12. Crawford DJ, Maddocks JL, Jones DN, et al. Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. J Med Chem 1996; 39: 2690-5. (Pubitemid 26240336)
13. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109-11.
14. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-45. (Pubitemid 36519931)
15. Vogt MH, Stet EH, De Abreu RA, et al. The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts. Biochim Biophys Acta 1993; 1181: 189-94. (Pubitemid 23124659)
16. Martin LK, Werth V, Villanueva E, et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; CD006263.
17. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57: 622-8. (Pubitemid 47384928)
18. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006; 142: 1447-54. (Pubitemid 44790638)
19. Pisoni CN, Karim Y, Cuadrado MJ,. Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 2005; 14 (Suppl. 1): s9-11. (Pubitemid 40460510)
20. Callen JP, Spencer LV, Burruss JB, et al. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991; 127: 515-22.
21. Tsokos GC, Caughman SW, Klippel JH,. Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Arch Dermatol 1985; 121: 1323-5. (Pubitemid 15248078)
22. Ashinoff R, Werth VP, Franks AG Jr,. Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 1988; 19: 961-5. (Pubitemid 18266023)
23. Iorizzo LJ III, Jorizzo JL,. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol 2008; 59: 99-112.
24. Choy EH, Hoogendijk JE, Lecky B, et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005; CD003643.
25. Miller J, Walsh Y, Saminaden S, et al. Randomized double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 2002; 199 (Suppl.): S53. (Abstract).
26. Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998; 41: 392-9. (Pubitemid 28128762)
27. Ponyi A, Constantin T, Balogh Z, et al. Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis. Clin Exp Rheumatol 2005; 23: 50-6. (Pubitemid 40424758)
28. Ng YT, Ouvrier RA, Wu T,. Drug therapy in juvenile dermatomyositis: follow-up study. J Child Neurol 1998; 13: 109-12. (Pubitemid 28185795)
29. Hofmann SC, Kautz O, Hertl M, et al. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges 2009; 7: 227-33.
30. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010; CD002292.
31. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007; 143: 1536-42. (Pubitemid 350277770)
32. Bystryn JC,. Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid. Arch Dermatol 2008; 144: 946.
33. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002; 147: 324-30.
34. Meggitt SJ, Gray JC, Reynolds NJ,. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006; 367: 839-46. (Pubitemid 43363371)
35. Murphy GM, Maurice PD, Norris PG, et al. Azathioprine treatment in chronic actinic dermatitis: a double-blind controlled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol 1989; 121: 639-46. (Pubitemid 19275252)
36. Du Vivier A, Munro DD, Verbov J,. Treatment of psoriasis with azathioprine. Br Med J 1974; 1: 49-51.
37. Dalaker M, Bonesronning JH,. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J Eur Acad Dermatol Venereol 2009; 23: 277-82.
38. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990; 322: 281-5. (Pubitemid 20046329)
39. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44. (Pubitemid 36765101)
40. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790-803.
41. Heurkens AH, Westedt ML, Breedveld FC,. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 1991; 151: 2249-54.
42. Zaffanello M, Brugnara M, Franchini M,. Therapy for children with Henoch-Schönlein purpura nephritis: a systematic review. ScientificWorldJournal 2007; 7: 20-30. (Pubitemid 46104911)
43. Chartapisak W, Opastirakul S, Hodson EM, et al. Interventions for preventing and treating kidney disease in Henoch-Schönlein purpura (HSP). Cochrane Database Syst Rev 2009; CD005128.
44. Chow RK, Ho VC,. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996; 34: 1047-60. (Pubitemid 26170772)
45. Hunter GA, Forbes IJ,. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol 1972; 87: 42-5.
46. Higgs JE, Payne K, Roberts C, et al. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 2010; 11: 177-88.
47. Gisbert JP, Nino P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 2006; 101: 2769-76. (Pubitemid 44902649)
48. Lindqvist M, Hindorf U, Almer S, et al. No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids 2006; 25: 1033-7. (Pubitemid 44651843)
49. Tassaneeyakul W, Srimarthpirom S, Reungjui S, et al. Azathioprine-induced fatal myelosuppression in a renal-transplant recipient who carried heterozygous TPMT*1/*3C. Transplantation 2003; 76: 265-6. (Pubitemid 36877151)
50. Firooz A, Ghandi N, Hallaji Z, et al. Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris. Arch Dermatol 2008; 144: 1143-7.
51. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-50.
52. Corominas H, Domenech M, Laiz A, et al. Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatology 2003; 42: 40-5. (Pubitemid 36131565)
53. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 395-400. (Pubitemid 37070237)
54. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-36. (Pubitemid 34918619)
55. Sayani FA, Prosser C, Bailey RJ, et al. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can J Gastroenterol 2005; 19: 147-51. (Pubitemid 40561782)
56. Gisbert JP, Luna M, Maté J, et al. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 2006; 53: 399-404. (Pubitemid 43954416)
57. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30. (Pubitemid 30346978)
58. Lennard L,. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002; 51: 143-6. (Pubitemid 34791433)
59. Murphy LA, Atherton D,. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol 2002; 147: 308-15.
60. Snow JL, Gibson LE,. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131: 193-7.
61. Meggitt SJ, Reynolds NJ,. Azathioprine for atopic dermatitis. Clin Exp Dermatol 2001; 22: 369-75. (Pubitemid 32863085)
62. Bezier M, Reguiai Z, Vitry F, et al. Thiopurine S-methyltransferase genotypic analysis in autoimmune bullous diseases. Eur J Dermatol 2008; 18: 512-17.
63. el-Azhary RA, Farmer SA, Drage LA, et al. Thioguanine nucleotides and thiopurine methyltransferase in immunobullous diseases: optimal levels as adjunctive tools for azathioprine monitoring. Arch Dermatol 2009; 145: 644-52.
64. Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2: 410-17. (Pubitemid 38561239)
65. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 973-83.
66. Achkar JP, Stevens T, Easley K, et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 339-45. (Pubitemid 39029175)
67. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13. (Pubitemid 30171620)
68. Cuffari C, Hunt S, Bayless TM,. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000; 14: 1009-14. (Pubitemid 30618161)
69. Bergan S, Rugstad HE, Bentdal O, et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation 1998; 66: 334-9. (Pubitemid 28390215)
70. Reinshagen M, Schutz E, Armstrong VW, et al. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007; 53: 1306-14. (Pubitemid 47020987)
71. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-53.
72. Wusk B, Kullak-Ublick GA, Rammert C, et al. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol 2004; 16: 1407-13. (Pubitemid 39627545)
73. Hindorf U, Johansson M, Eriksson A, et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 654-61.
74. Parnham AP, Dittmer I, Mathieson PW, et al. Acute allergic reactions associated with azathioprine. Lancet 1996; 348: 542-3. (Pubitemid 26279020)
75. King JO, Laver MC, Fairley KF, et al. Sensitivity to azathioprine. Med J Aust 1972; 2: 939-41.
76. Meggitt SJ,. Azathioprine for Atopic Eczema, MD Thesis. Newcastle University, Newcastle upon Tyne, UK, 2006.
77. Bir K, Herzenberg AM, Carette S, et al. Azathioprine induced acute interstitial nephritis as the cause of rapidly progressive renal failure in a patient with Wegener's granulomatosis. J Rheumatol 2006; 33: 185-7. (Pubitemid 43054300)
78. Sloth K, Thomsen AC,. Acute renal insufficiency during treatment with azathioprine. Acta Med Scand 1971; 189: 145-8.
79. Sinico RA, Sabadini E, Borlandelli S, et al. Azathioprine hypersensitivity: report of two cases and review of the literature. J Nephrol 2003; 16: 272-6. (Pubitemid 37304085)
80. de Fonclare AL, Khosrotehrani K, Aractingi S, et al. Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease. Arch Dermatol 2007; 143: 744-8. (Pubitemid 46955733)
81. Ananthakrishnan AN, Attila T, Otterson MF, et al. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007; 41: 682-8. (Pubitemid 47220474)
82. Alexander S, Dowling D,. Azathioprine pancreatitis in inflammatory bowel disease and successful subsequent treatment with mercaptopurine. Intern Med J 2005; 35: 570-1. (Pubitemid 41291390)
83. Weersma RK, Peters FT, Oostenbrug LE, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther 2004; 20: 843-50. (Pubitemid 39424891)
84. Knowles S, Shear NH,. Azathioprine hypersensitivity reactions: caution upon rechallenge. Muscle Nerve 1997; 20: 1467-8. (Pubitemid 27446879)
85. Lees CW, Maan AK, Hansoti B, et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 220-7.
86. Davis M, Eddleston AL, Williams R,. Hypersensitivity and jaundice due to azathioprine. Postgrad Med J 1980; 56: 274-5. (Pubitemid 10147321)
87. Stetter M, Schmidl M, Krapf R,. Azathioprine hypersensitivity mimicking Goodpasture's syndrome. Am J Kidney Dis 1994; 23: 874-7. (Pubitemid 24173574)
88. Bowen DG, Selby WS,. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000; 45: 1810-13.
89. Anstey A, Lennard L, Mayou SC, et al. Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med 1992; 85: 752-6.
90. Winkelstein A,. The effects of azathioprine and 6 MP on immunity. J Immunopharmacol 1979; 1: 429-54. (Pubitemid 11239064)
91. Gupta G, Lautenbach E, Lewis JD,. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483-90. (Pubitemid 44880029)
92. Ahmed AM, Brantley JS, Madkan V, et al. Managing herpes zoster in immunocompromised patients. Herpes 2007; 14: 32-6. (Pubitemid 47556307)
93. Lawson DH, Lovatt GE, Gurton CS, et al. Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev 1984; 3: 161-71. (Pubitemid 14001001)
94. Millar JW, Horne NW,. Tuberculosis in immunosuppressed patients. Lancet 1979; 1: 1176-8. (Pubitemid 9190882)
95. Gisbert JP, Gonzalez-Lama Y, Mate J,. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007; 102: 1518-27. (Pubitemid 46976279)
96. Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 22: 775-82. (Pubitemid 41564356)
97. Nygaard U, Toft N, Schmiegelow K,. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004; 75: 274-81. (Pubitemid 38471553)
98. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15. (Pubitemid 34267273)
99. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 2007; 102: 2488-94. (Pubitemid 47631795)
100. Taylor AE, Shuster S,. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol 1992; 72: 115-19.
101. McLelland J, Rees A, Williams G, et al. The incidence of immunosuppression-related skin disease in long-term transplant patients. Transplantation 1988; 46: 871-4. (Pubitemid 19013234)
102. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Skin cancers in organ transplant recipients. Ann Transplant 1997; 2: 28-32.
103. Maddox JS, Soltani K,. Risk of nonmelanoma skin cancer with azathioprine use. Inflamm Bowel Dis 2008; 14: 1425-31.
104. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268-74.
105. Brem R, Li F, Karran P,. Reactive oxygen species generated by thiopurine/UVA cause irreparable transcription-blocking DNA lesions. Nucleic Acids Res 2009; 37: 1951-61.
106. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-4. (Pubitemid 41325100)
107. Perrett CM, Walker SL, O DP, et al. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008; 159: 198-204. (Pubitemid 351874494)
108. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV. Long-term management of the transplant recipient. IV.6.2. Cancer risk after renal transplantation. Skin cancers: prevention and treatment. Nephrol Dial Transplant 2002; 17 (Suppl. 4): 31-6.
109. Ulrich C, Stockfleth E,. Azathioprine, UV light, and skin cancer in organ transplant patients-do we have an answer? Nephrol Dial Transplant 2007; 22: 1027-9. (Pubitemid 46523414)
110. Karran P, Attard N,. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008; 8: 24-36.
111. Jones JL, Loftus EV Jr,. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007; 13: 1299-307. (Pubitemid 47597781)
112. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-5. (Pubitemid 41025906)
113. Sondheimer JM,. Lymphoma after Imuran and 6-MP: a new look. J Pediatr Gastroenterol Nutr 2005; 41: 683-4. (Pubitemid 41579686)
114. Masunaga Y, Ohno K, Ogawa R, et al. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 2007; 41: 21-8. (Pubitemid 46145952)
115. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
116. Vos ACW, Bakkal N, Minnee RC, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 2011; 17: 1837-45.
117. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-52. (Pubitemid 24158045)
118. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009; 339: b2480.
119. Summary of Product Characteristics. Imuran Tablets 50 mg. 2010. Available at: (last accessed 2 August 2011).
120. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-2. (Pubitemid 36020781)
121. Derijks LJ, van Helden RB, Hommes DW, et al. Dosing azathioprine in thiopurine S-methyltransferase deficient inflammatory bowel disease patients. Gut 2008; 57: 872. (Pubitemid 351716984)
122. Gardiner SJ, Gearry RB, Begg EJ, et al. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol 2008; 6: 654-60; quiz 04.
123. Korelitz BI, Reddy B, Bratcher J,. Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease. Expert Opin Drug Saf 2010; 9: 379-82.
124. Fargher EA, Tricker K, Newman W, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007; 32: 187-95. (Pubitemid 46449703)
125. Yip JS, Woodward M, Abreu MT, et al. How are azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis 2008; 14: 514-18. (Pubitemid 351571831)
126. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006; 55: 1423-31. (Pubitemid 44476786)
127. Arenas M, Duley JA, Ansari A, et al. Genetic determinants of the pre- and post-azathioprine therapy thiopurine methyltransferase activity phenotype. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1403-5. (Pubitemid 39625933)
128. Payne K, Newman W, Fargher E, et al. TPMT testing in rheumatology: any better than routine monitoring? Rheumatology 2007; 46: 727-9. (Pubitemid 47061698)
129. Joint Formulary Committee. British National Formulary, 61. London: British Medical Association and Royal Pharmaceutical Society, 2011.
130. Schusziarra V, Ziekursch V, Schlamp R, et al. Pharmacokinetics of azathioprine under haemodialysis. Int J Clin Pharmacol Biopharm 1976; 14: 298-302.
131. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
132. Colbert C, Chavarria A, Berkelhammer C,. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007; 13: 1453-4. (Pubitemid 350206866)
133. Wursthorn K, Wedemeyer H, Manns MP,. Managing HBV in patients with impaired immunity. Gut 2010; 59: 1430-45.
134. Gunji Y, Sakamoto K, Sato S, et al. Acutely exaggerated hepatitis B induced by the withdrawal of immunosuppressants in a seroconverted renal transplant recipient: report of a case. Surg Today 2002; 32: 472-5. (Pubitemid 34591764)
135. Bhagani S, Sweny P, Brook G,. Guidelines for kidney transplantation in patients with HIV disease. HIV Med 2006; 7: 133-9.
136. Roland ME, Adey D, Carlson LL, et al. Kidney and liver transplantation in HIV-infected patients: case presentations and review. AIDS Patient Care STDS 2003; 17: 501-7. (Pubitemid 37337528)
137. Department of Health. The Green Book: Immunisation Against Infectious Disease. Chapter 6: Contraindications and special considerations. 2006. updated 17 September 2008. Available at: http://www.dh.gov.uk/prod-consum-dh/groups/dh- digitalassets/@dh/@en/documents/digitalasset/dh-063623.pdf (last accessed 2 August 2011).
138. Centers for Disease Control and Prevention. Guide to Vaccine Contraindications and Precautions. 2009. Available at: (last accessed 2 August 2011).
139. Jordan J, Martin-Hirsch P, Arbyn M, et al. European guidelines for clinical management of abnormal cervical cytology, part 2. Cytopathology 2009; 20: 5-16.
140. ter Haar-van Eck SA, Rischen-Vos J, Chadha-Ajwani S, et al. The incidence of cervical intraepithelial neoplasia among women with renal transplant in relation to cyclosporine. Br J Obstet Gynaecol 1995; 102: 58-61.
141. Dejaco C, Mittermaier C, Reinisch W, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2001; 121: 1048-53. (Pubitemid 33022083)
142. Xu L, Han S, Liu Y, et al. The influence of immunosuppressants on the fertility of males who undergo renal transplantation and on the immune function of their offspring. Transpl Immunol 2009; 22: 28-31.
143. Gisbert JP,. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2009; 16: 881-95.
144. Patel AA, Swerlick RA, McCall CO,. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006; 55: 369-89. (Pubitemid 44189574)
145. Oefferlbauer-Ernst A, Reinisch W, Miehsler W, et al. Healthy offspring in parents both receiving thiopurines. Gastroenterology 2004; 126: 628. (Pubitemid 38182324)
146. Gardiner SJ, Gearry RB, Roberts RL, et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 2006; 62: 453-6. (Pubitemid 44401528)
147. Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28: 1209-13.
148. Grossman AB, Noble AJ, Mamula P, et al. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm Bowel Dis 2008; 14: 750-5. (Pubitemid 351898058)
149. Meier-Kriesche HU, Ojo A, Hanson J, et al. Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation 2000; 69: 885-9. (Pubitemid 30174116)
150. el-Gamel A, Evans C, Keevil B, et al. Effect of allopurinol on the metabolism of azathioprine in heart transplant patients. Transplant Proc 1998; 30: 1127-9. (Pubitemid 28309509)
151. Kennedy DT, Hayney MS, Lake KD,. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996; 30: 951-4. (Pubitemid 26295245)
152. Vazquez SR, Rondina MT, Pendleton RC,. Azathioprine-induced warfarin resistance. Ann Pharmacother 2008; 42: 1118-23.
153. Ng HJ, Crowther MA,. Azathioprine and inhibition of the anticoagulant effect of warfarin: evidence from a case report and a literature review. Am J Geriatr Pharmacother 2006; 4: 75-7.
154. Peyrin-Biroulet L, Cadranel JF, Nousbaum JB, et al. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment Pharmacol Ther 2008; 28: 984-93.
155. Chaparro M, Trapero-Marugan M, Moreno-Otero R, et al. Azathioprine plus ribavirin treatment and pancytopenia. Aliment Pharmacol Ther 2009; 30: 962-3.
156. Keshtkar-Jahromi M, Argani H, Rahnavardi M, et al. Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: a controlled trial. Am J Nephrol 2008; 28: 654-60. (Pubitemid 351832453)
157. Shah JA, Edwards CM, Probert CS,. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease? An audit of adverse events and outcome. Eur J Gastroenterol Hepatol 2008; 20: 169-73. (Pubitemid 351317352)
158. Dretchen KL, Morgenroth VH III, Standaert FG, et al. Azathioprine: effects on neuromuscular transmission. Anesthesiology 1976; 45: 604-9.
159. Glidden RS, Martyn JA, Tomera JF,. Azathioprine fails to alter the dose-response curve of d-tubocurarine in rats. Anesthesiology 1988; 68: 595-8.
160. Xin HW, Fischer C, Schwab M, et al. Thiopurine S-methyltransferase as a target for drug interactions. Eur J Clin Pharmacol 2005; 61: 395-8. (Pubitemid 41569315)
161. Lysaa RA, Giverhaug T, Wold HL, et al. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol 1996; 49: 393-6. (Pubitemid 26060989)
162. Oselin K, Anier K,. Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions. Drug Metab Dispos 2007; 35: 1452-4. (Pubitemid 47296070)
163. Gossmann J, Kachel HG, Schoeppe W, et al. Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation 1993; 56: 585-9. (Pubitemid 23293020)
164. Gossmann J, Thurmann P, Bachmann T, et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996; 50: 973-8. (Pubitemid 26302687)
165. Ford LT, Berg JD,. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol 2010; 63: 288-95.
166. Winter JW, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25: 1069-77. (Pubitemid 46587697)
167. Compagni A, Bartoli S, Buehrlen B, et al. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. Int J Technol Assess Health Care 2008; 24: 294-302. (Pubitemid 351950165)
168. Richard VS, Al-Ismail D, Salamat A,. Should we test TPMT enzyme levels before starting azathioprine? Hematology 2007; 12: 359-60. (Pubitemid 47180666)
169. Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 85: 164-72.
170. Uchiyama K, Nakamura M, Kubota T, et al. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. J Gastroenterol 2009; 44: 197-203.
171. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14: 181-7. (Pubitemid 38373112)
172. Von Ahsen N, Oellerich M, Armstrong VW,. Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function. Ther Drug Monit 2008; 30: 16-22. (Pubitemid 351161094)
173. Van Dieren JM, Hansen BE, Kuipers EJ, et al. Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2007; 26: 643-52. (Pubitemid 47246201)
174. Gearry RB, Roberts RL, Barclay ML, et al. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004; 14: 779-81. (Pubitemid 39552794)
175. Kurzawski M, Dziewanowski K, Lener A, et al. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol 2009; 65: 533-40.
176. Allorge D, Hamdan R, Broly F, et al. ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6- mercaptopurine induced myelosuppression. Gut 2005; 54: 565. (Pubitemid 40395509)
177. Smith MA, Marinaki AM, Arenas M, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther 2009; 30: 375-84.
178. Hindorf U, Jahed K, Bergquist A, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010; 52: 106-11.
179. Elion GB,. The purine path to chemotherapy. Science 1989; 244: 41-7. (Pubitemid 19130741)
180. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5: 209-14. (Pubitemid 46216945)
181. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22: 441-6. (Pubitemid 41248111)
182. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 640-7.
183. Ansari A, Elliott T, Baburajan B, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 734-41.